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Abstract 
The Cell Ontology (CL) aims for the representation 
of in vivo and in vitro cell types from all of biology.  
Although the CL is a reference ontology of the OBO 
Foundry, it requires extensive revision to bring it up 
to current standards for biomedical ontologies, both 
in its structure and its coverage of various subfields 
of biology.  A recent workshop sponsored by NIAID 
on hematopoietic cell types in the CL addressed both 
issues.  The section of the ontology dealing with 
hematopoietic cells was extensively revised, and 
plans were set for structuring these cell type terms as 
cross-products with logical definitions built from 
relationships to external ontologies, such as the 
Protein Ontology and the Gene Ontology.  The 
methods and improvement to the CL in this area 
represent a paradigm for improvement of the whole 
of the ontology over time. 
Overview 
The Cell Ontology (CL) is an OBO Foundry 
candidate ontology originally built to represent in 
vivo and in vitro cell types, including developmental 
stages, of all the major model organisms.1  The CL 
now aims to become a reference ontology within the 
OBO Foundry.2  The CL both serves the terminology 
needs of data annotation, and provides a base 
ontology from which compound terms in other 
ontologies can be derived by means of cross-product 
term formation.3  At Mouse Genome Informatics, the 
CL is used in conjunction with Gene Ontology (GO) 
annotation of mouse gene products to indicate the 
cell type in which a gene product is active.  The GO 
itself uses CL terms in the formation of new GO 
terms:  for instance, the GO term “leukocyte 
differentiation” is a cross-product of the CL term 
“leukocyte” with the GO term “cell differentiation.” 
The Cell Ontology is constructed using two 
relationships, is_a and develops_from.  The first 
relationship is used to build an ontology of cellular 
subtypes; the latter relationship is used to indicate 
cell lineage relationships.  The ontology as it was 
initially developed relied upon a number of artificial 
high level terms to capture types of cellular qualities, 
such as “cell in vivo,” “cell by organism,” and “cell 
by class,” a term which itself has the is_a child terms 
“cell by function,” “cell by histology,” “cell by 
lineage,” “cell by ploidy,” etc.  These subclasses of 
cells have further is_a children denoting more 
specific qualities of cells. Depending on the qualities 
of a particular cell type it may have one or more of 
these terms as is_a ancestors.  For instance, the well-
defined cell type “erythrocyte” is a type of “erythroid 
lineage cell,” “oxygen accumulating cell,” 
“transporting cell,” and “blood cell.”  It also has a 
develops_from relationship with “reticulocyte.” 
With its multiple inheritance structure, the original 
CL could be described as having separate ontologies 
of cell types delineated by particular cellular qualities 
overlaid upon each other, i.e. an ontology with 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
09
.3
63
5.
1 
: P
os
te
d 
17
 A
ug
 2
00
9
multiple axes of differentia that are variously and 
sometimes arbitrarily applied to individual cell types.  
Furthermore the high level terms themselves are not 
actual cell types, so the ontology is not a true is_a 
hierarchy.  This unwieldy ontological construct is not 
ideal for developing proper inference about cell 
types, nor does it always provide obvious placement 
of new cell type terms. 
Informal discussions among interested parties in the 
past few years have focused on how best to 
restructure the CL to eliminate the complexity of its 
multiple inheritance structure with the aim of finding 
a single axis of differentia upon which to base the 
ontology.  Participants in these general discussions 
about the CL gradually recognized that no consistent 
differentia such as cellular structure or lineage can 
adequately describe all cell types, and that the best 
solution for biologists is to represent the differences 
and relations between cell types as scientists working 
in various subfields of biology do, depending on their 
specific criteria for differentiating cell types. 
Other criticisms about the CL include the fact that 
many terms do not have definitions or a complete set 
of synonyms.  Also, cell types in many subfields of 
biology are poorly represented within the CL.  A 
compounding issue has been the lack of a full-time 
curator for the ontology as a whole.  Efforts at 
improvement have been made in certain areas of the 
ontology, and hematopoietic cell types in particular 
have been the focus of two rounds of intensive 
curation in recent years.  Here we report on these 
revisions and examine the process as an example for 
the future development of the Cell Ontology. 
Hematopoietic Cell Type Revisions 
The first set of improvements for hematopoietic cells 
was done in 2006 in conjunction with the revision of 
the terms for immunological processes in the GO.4,5  
At that time 80 new hematopoietic cell type terms 
were introduced, many other terms were revised, and 
many improvements in ontology structure were made 
for these cell types. 
A second, larger round of revisions to the 
hematopoietic cell type terms in CL is described 
herein.  These revisions are the product of a National 
Institute of Allergy and Infectious Disease (NIAID) 
sponsored “Workshop on Immune Cell 
Representation in the Cell Ontology,” held in May 
2008, where domain experts and biomedical 
ontologists worked together on two goals: 1) revising 
and developing additional specific terms for T cells, 
B cells, natural killer cells, monocytes and 
macrophages, and dendritic cells, and 2) establishing 
a new paradigm for development of the CL.  These 
changes in the representation of hematopoietic cells 
were needed to represent these cell types in a more 
complete manner so that all major cell types 
identified in the literature are found in the ontology 
and so that these cell types are defined in an in-depth 
manner that greatly increases the descriptiveness of 
the ontology for data annotation and logical 
inference. 
Methods 
The NIAID workshop attendees discussed both 
specific groups of cell types of interest to 
immunologists as well as how to improve the overall 
ontological structure of these groups and the CL 
ontology in general.  The consensus view was that 
the current multiple inheritance structure of the CL is 
unsustainable and that existing and new terms for 
hematopoietic cells should be logically defined via 
their qualities as represented in other ontologies.  
Much discussion centered on what might be the 
optimal axis of differentia for these hematopoietic 
terms. It was recognized in many cases that these cell 
types are defined largely, but not solely, by the 
expression of particular marker proteins either at the 
cell surface (e.g. receptor proteins) or internally (e.g. 
transcription factors).  The presence of these proteins 
as part of a cell is considered a structural feature of 
the cell, and participants agreed that the relationship 
has_part from the OBO relationship ontology would 
be used to relate particular cell types to protein terms 
from the Protein Ontology.6,7 
However, for certain cell types, such as macrophages, 
it was seen that the full molecular characterization of 
different types of macrophages is still not complete in 
the literature, and that anatomical location serves as a 
major differentia for these cells.  For other cell types, 
functional or lineage criteria serve as differentia for 
the complete definition of the cells.  Functional 
criteria include the ability to execute or participate in 
particular GO processes that relate to individual cells, 
such as “cytotoxicity” or “cytokine production,” or 
GO processes that involve coordination of multiple 
cell types, such as “T-helper 1 type immune 
response.”  Thus, the participants at the workshop 
agreed to focus on structural criteria where possible 
as the primary differentia, but to accept other types of 
differentia when necessary.  This flexibility should 
make it possible to stick to the commonly accepted 
biological definitions of individual cell types and to 
organize the ontology according to sound ontological 
principles while still reflecting organization of 
hematopoietic cell types seen in the literature. 
The primary goal in revising the hematopoietic cell 
terms is to define all the terms according to logical 
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definitions based on relationships to external 
ontologies.  The workshop participants recognized 
that reaching the full development of these terms as 
cross-products would be difficult at this time due to 
the lack of a full-time curator for the CL.  Also, 
external ontologies, such as the Protein Ontology, are 
not yet complete in all the required terms.  Yet at the 
same time, the new hematopoietic cell terms are 
needed for data annotation and development of cross-
products in the GO and other ontologies. 
Results:  A Two-Stage Process 
Reflecting the above considerations, the participants 
at the NIAID workshop agreed upon a two-stage 
approach to further development of the hematopoietic 
cells in the Cell Ontology.  In the first stage, which is 
now complete, current terms were revised and new 
terms added by the experts at the workshop.  The 
textual definitions for these terms contain all the 
necessary details to define the cells logically.  These 
terms have been directly incorporated into the 
existing ontology.  It was also decided to separate the 
hematopoietic terms from the multiple inheritance 
hierarchy of the original CL as much as possible, so 
that the section of the ontology containing these 
terms represents a true ontology hierarchy.  This first-
stage ontology has been given the working name 
“CL1.5.”  Figure 1A shows a typical OBO term 
stanza for one of these new terms, “induced T-
regulatory cell.” 
The second stage will then be the development of the 
hematopoietic terms into full cross-products as 
discussed above.  The extended definitions provided 
in the first step will hopefully enable this to be done 
in a fairly efficient manner depending upon the 
availability of the necessary terms in external 
ontologies.  Ideally, this approach will be extended to 
the whole of the CL to create version “CL2.0.”  For 
the moment we plan to develop the hematopoietic 
terms of the CL into an external mini-ontology based 
on these cross products, “hemo-CL.”  Figure 1B 
shows the OBO term stanza for term “induced T-
regulatory cell” as it will be represented in hemo-CL 
and CL2.0, illustrated graphically in Figure 1C.  We 
have already been working with the curators of the 
Protein Ontology to ensure that protein terms needed 
A 
id: CL:0000902 
name: induced T-regulatory cell 
def: "CD4-positive alpha-beta T cell with the phenotype 
CD25-positive, CTLA-4-positive, and FoxP3-positive with 
regulatory function." 
is_a: CL:0000792 ! CD4-positive, CD25-positive, alpha-
beta regulatory T cell 
relationship: develops_from CL:0000896 ! activated CD4-
positive, alpha-beta T cell 
 
B 
id: CL:0000902 
name: induced T-regulatory cell 
def: "CD4-positive alpha-beta T cell with the phenotype 
CD25-positive, CTLA-4-positive, and FoxP3-positive with 
regulatory function." 
intersection_of: CL:0000792 ! CD4-positive, CD25-positive, 
alpha-beta regulatory T cell 
intersection_of: has_part PRO:000001380 ! CD25 
intersection_of: has_part PRO:000001852 ! CTLA-4 
intersection_of: has_part PRO:000001350 ! FoxP3 
intersection_of: participates_in GO:0050776 ! regulation of 
immune response 
relationship: develops_from CL:0000896 ! activated CD4-
positive, alpha-beta T cell 
C 
 
Figure 1.  Examples of improvement in the representation of hematopoietic cells. 
A. OBO term stanza representative of CL1.5 term definitions for the term “induced T-regulatory cell.”  
B. OBO term stanza representative of CL2.0 showing logical definition of the same term as in A. 
C. Graphical view of the term relationships in B. 
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for hemo-CL are found in the Protein Ontology. 
The initial step towards hemo-CL and CL2.0 has 
been taken by Masci and colleagues, who have 
developed a dendritic cell ontology, DC-CL, which is 
based on cross-product principles and is the 
foundation of the revised dendritic cell terms in 
CL1.5.8  DC-CL terms for types of dendritic cells are 
primarily based on structural criteria (surface protein 
expression) with a few cell types also defined by 
relationships to functions or dispositions. DC-CL 
utilizes an expanded range of relationship types based 
on those in the relationship ontology in order to be 
more expressive about the cellular location and 
degree of protein expression (has_membrane_part, 
has_high_membrane_amount).  It is likely that 
similar relationships will be employed in the 
construction of hemo-CL and CL2.0. 
Specific Improvements in the Representation of 
Hematopoietic Cell Types 
With the work initiated at the NIAID workshop and 
carried on afterwards, many concrete improvements 
to CL content in the area of hematopoietic cells have 
been achieved.   Many new terms for individual cell 
types have been created, including over 40 terms for 
T-lineage cells, over 40 terms for B-lineage cells, 
several natural killer cell terms, over 30 terms for 
monocytes and macrophages, and over 30 terms for 
dendritic cells.  Other new terms were introduced for 
various hematopoietic progenitor cell types.  As 
discussed above, most of these new terms have been 
defined by structural criteria (protein expression) 
sometimes in conjunction with functional or 
anatomical relationships.  The exception to this 
general rule is that most of the new macrophage 
terms are defined based on their anatomical location 
with protein expression criteria added where 
supported by the literature. 
The ontology structure has been improved as well in 
important areas such as T cell and B cell 
development.  Lineage relationships via the 
develops_from relationship have been provided for 
many additional cell types.  In general the 
hematopoietic terms are intended to be species 
neutral, but species-specific information has been 
incorporated in some definitions where necessary and 
comments added to provide clarity to data annotators. 
Discussion 
The Cell Ontology is an essential core component of 
the OBO Foundry and has great potential for aiding 
data annotation and analysis.  With the improvements 
described herein, implemented for CL1.5, and 
planned for hemo-CL/CL2.0, we expect the CL to 
fulfill much more of its promise in the area of 
hematopoietic cell representation.  The ontology now 
has fairly complete coverage of these cell types in an 
improved hierarchy and using up-to-date molecular 
definitions.  These changes will provide for more 
robust inference across the ontology and greater 
utility for annotation of hematopoietic cell type data, 
and will strengthen the use of the CL as a reference 
ontology for cross-product development. 
The workshop approach, aided by an acting editor for 
this section of the ontology, has worked reasonably 
well in carrying out the needed additions and 
revisions in the ontology content in this area, and in 
outlining a clear plan for the future of the ontology.  
The section-by-section approach for improvement of 
defined parts of the Cell Ontology represents a 
paradigm for continued development of the CL and 
should prove even more useful once dedicated 
funding is achieved. 
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